Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I

04-Jan-2024 - Evotec SE and Owkin, a French-American techbio startup announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation (“I&I”). The collaboration brings together highly complementary platforms and expertise to accurately select targets, discover and ...

Evotec and Dewpoint Therapeutics enter strategic partnership in oncology

Agreement is based on a risk-sharing arrangement followed by milestone and royalty payments to Evotec based on success of overall programmes

08-Nov-2023 - Evotec SE and Dewpoint Therapeutics announced a strategic R&D collaboration to advance Dewpoint’s leading oncology pipeline programmes of condensate modifying therapeutics (“c-mods”) to Investigational New Drug Applications (“INDs”) using Evotec’s industry-leading fully integrated data-driven ...

Evotec receives US$ 6.6 m grant for drug discovery in tuberculosis

24-Mar-2023 - Evotec SE announced that the Company has received a US$ 6.6 m grant from The Bill & Melinda Gates Foundation for drug discovery in tuberculosis (“TB”). The grant is the second award from the foundation to Evotec supporting TB drug discovery, and allows the Company to progress a portfolio of TB ...

Evotec achieves milestone in its neurodegeneration collaboration with Bristol Myers Squibb

Evotec receive a US$ 6 m payment

05-Jan-2021 - Evotec SE announced that the Company has received a US$ 6 m payment from Bristol Myers Squibb Company within the companies’ iPSC-based neuroscience partnership. The payment follows Bristol Myers Squibb’s decision to add another drug discovery project to the partnership’s portfolio. Evotec and ...

Drug discovery with artificial intelligence

Evotec participates in Exscientia's financing round

29-May-2020 - Evotec SE announced that the Company has participated in the Series C funding round of Exscientia, the Artificial Intelligence (AI)-driven drug discovery company. The funding round led by new investor Novo Holdings raised $ 60 m with the existing investors’ consortium consisting of Evotec, ...

Evotec and Takeda enter into multi-year gene therapy research alliance

07-Apr-2020 - Evotec SE announced that Evotec GT, with operations in Austria, has established a long-term research alliance with Takeda to support Takeda’s growing number of research stage gene therapy discovery programmes. Under the alliance, Evotec will support multiple Takeda programmes targeting conditions ...

Evotec reaches milestone in integrated drug discovery and development partnership with Aeovian

07-Oct-2019 - Evotec SE announced that the Company has reached a milestone in a drug discovery and development partnership with the biopharmaceutical company Aeovian Pharmaceuticals, Inc. Aeovian and Evotec entered into a drug discovery partnership in 2017 to discover and develop new and highly selective ...

Evotec and Takeda enter collaboration agreement to discover clinical candidates across multiple therapeutic areas

24-Sep-2019 - Evotec SE announced a strategic, multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited. Under the collaboration, the parties aim to establish at least five drug discovery programmes with the goal of Evotec delivering clinical candidates for Takeda to pursue into ...

Evotec and LEO Pharma form drug discovery alliance targeting dermatological conditions

05-Dec-2018 - Evotec AG announced a new integrated drug discovery alliance with LEO Pharma. The collaboration goal is to generate new leads against innovative targets for a range of dermatological conditions and initially runs for two years. The collaboration leverages Evotec’s industry-leading hit ...

Evotec enters into an integrated drug discovery collaboration with Asahi Kasei Pharma

19-Jan-2017 - Evotec AG announced it has entered into an integrated drug discovery collaboration on an ion channel target with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan. Under the terms of the agreement, Evotec will apply its integrated drug discovery ...